Rein Therapeutics (RNTX) Interest Expenses (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Interest Expenses of $319000.0 for Q1 2026, down 65.06% year-over-year from $913000.0 in Q1 2025, and up 101.9% quarter-over-quarter from $158000.0 in Q4 2025.
Rein Therapeutics (RNTX) Interest Expenses (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Interest Expenses for 11 consecutive years, with $319000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 65.06% year-over-year to $319000.0; the TTM figure through Mar 2026 stood at $319000.0 (down 65.06% YoY), while the FY2025 annual figure was $158000.0, down 99.48% from the prior year.
- Interest Expenses improved to $319000.0 in Q1 2026 per RNTX's latest filing, from $158000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $77.4 million in Q4 2022 and bottomed at $2000.0 in Q2 2023.
- Historically, Interest Expenses has averaged $9.0 million across 5 years, with a median of $384000.0 in 2025.
- Annual changes were most pronounced in 2024 — Interest Expenses soared 115150.0% — and 2025, when it sank 99.48%.
- Rein Therapeutics' Interest Expenses stood at $77.4 million in 2022, then tumbled by 76.1% to $18.5 million in 2023, then soared by 64.56% to $30.5 million in 2024, then tumbled by 99.48% to $158000.0 in 2025, then soared by 101.9% to $319000.0 in 2026.
- Business Quant data shows RNTX's Interest Expenses at $319000.0 in Q1 2026, $158000.0 in Q4 2025, and $153000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 461,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 461,000.00 |
| Jun 30, 2026 | 461,000.00 |
| Mar 31, 2026 | 319,000.00 |
| Mar 31, 2026 | 319,000.00 |
| Dec 31, 2025 | 158,000.00 |
| Dec 31, 2025 | 158,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 449,000.00 |
| Jun 30, 2025 | 449,000.00 |
| Mar 31, 2025 | 913,000.00 |
| Mar 31, 2025 | 913,000.00 |
| Dec 31, 2024 | 30.45 Mn |
| Dec 31, 2024 | 30.45 Mn |
| Sep 30, 2024 | 3.38 Mn |
| Sep 30, 2024 | 3.38 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 8.90 Mn |
| Mar 31, 2024 | 8.90 Mn |